End­points 20 un­der 40; Ver­dict on PI3K; Re­gen­eron goes dis­count shop­ping; $1.85B deal im­plodes; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The End­points News team is re­al­ly grow­ing. We’re ex­cit­ed to wel­come Lei Lei Wu and Tyler Patchen join­ing as our newest re­porters. For an il­lus­tra­tion of what a di­verse set of writ­ers could bring, look no fur­ther than this year’s End­points 20 un­der 40 — the per­spec­tives and ac­cents that every­one brings are sim­ply in­cred­i­ble. I hope you en­joy read­ing the spe­cial re­port as much as I did.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER